EZETIMIBE Drug Patent Profile
✉ Email this page to a colleague
When do Ezetimibe patents expire, and when can generic versions of Ezetimibe launch?
Ezetimibe is a drug marketed by Accord Hlthcare, Alkem Labs Ltd, Amneal Pharms Co, Apotex, Aurobindo Pharma, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Ohm Labs Inc, Orient Pharma, Rising, Sandoz, Sciegen Pharms Inc, Teva Pharms Usa, Watson Labs Inc, Zydus Pharms, Ani Pharms, Aurobindo Pharma Usa, and Dr Reddys Labs Sa. and is included in twenty-two NDAs.
The generic ingredient in EZETIMIBE is ezetimibe; simvastatin. There are twenty-four drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the ezetimibe; simvastatin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ezetimibe
A generic version of EZETIMIBE was approved as ezetimibe; simvastatin by DR REDDYS LABS SA on April 26th, 2017.
Summary for EZETIMIBE
Recent Clinical Trials for EZETIMIBE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
dotter | Phase 4 |
Novartis Pharmaceuticals | Phase 3 |
Organon and Co | Phase 4 |
Pharmacology for EZETIMIBE
Drug Class | Dietary Cholesterol Absorption Inhibitor |
Physiological Effect | Decreased Cholesterol Absorption |